PTC Therapeutics establishes international headquarters in Dublin, appoints Adrian Haigh head of EMEA

17 September 2014

US-based PTC Therapeutics (Nasdaq: PTCT) is to expand its global presence by adding key executives to leadership positions in the global commercial team and establishing its international headquarters in Dublin, Ireland.

Pre-launch activities are underway while PTC is preparing for the commercial launch of Translarna (ataluren) in the European Union for the treatment of nonsense mutation Duchenne muscular dystrophy, for which it received European Medicines Agency approval in August.

The company has appointed Adrian Haigh as senior vice president and general manager of the EMEA region, who joins PTC from Gentium SpA, where he was senior vice president of commercial operations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK